Estimating CV risk and treatment benefit
Clinical updates in management of cardiovascular risk (4/4)10' education - June 12, 2018 - Prof. Frank Visseren, MD - University Medical Center Utrecht, The Netherlands
Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.
Video navigation menu
- Risk estimation to translate results of RCTs to treatment of individuals 00:38
- CV risk estimation in the elderly 02:15
- SMART risk score for patients with clinical manifest vascular disease 05:39
- Estimating lifetime risk and treatment benefit 08:11
- CVD-free life expectancy for estimating lifetime benefit 10:44
- U-Prevent to calculate individual lifetime benefit of therapy. 12:18
This educational video is part of a series of 4 videos with the theme: Clinical Updates in Management of Cardiovascular Risk.
Educational objectives are:
- To review the epidemiology and current guidelines on the diagnosis, management, and treatment of patients at increased CV risk
- To understand the medical need for intensive risk interventions in patients at high CV risk, including diabetes
- To discuss new concepts in cardiovascular risk management including earlier and more intensive intervention and integrate scientific evidence from key clinical trials into practice
- To explore the role of new risk calculation models for cardiovascular risk estimation and communication
Professor Frank Visseren, MD - Internist, Epidemiologist and Professor in Vascular Medicine at the University Medical Center in Utrecht, The Netherlands.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Pfizer